Stock Ratings / Health Care / SHPH / financials

CRVO (28) CELU (26) MIRA (36) BYSI (37) ⌘ Pro Terminal →

Shuttle Pharmaceuticals Holdings Inc. (SHPH) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.15 -1.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.13

Shuttle Pharmaceuticals Holdings Inc. (SHPH) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $24.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SHPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SHPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $5.15 (-1.53% 1D, market cap $24.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SHPH compare to CRVO and CELU in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SHPH carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRVO (CervoMed Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $24.2M) and CELU (Celularity Inc. (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $26.0M). Among the 5-stock peer group, SHPH leads on earnings multiple (N/A) while SHPH leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SHPH?

▼

Per SHPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001757499), Shuttle Pharmaceuticals Holdings Inc. generated $0 in revenue, -$11.7M in net income, and -$9.5M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.13 (-0.47%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SHPH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY SHPH SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 57.4 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.18-5.2% Next Q

Q2 (-2Q)

Grade D$4.91+6.1% Next Q

Q3 (-1Q)

Grade D$5.21-1.2% Next Q

Current

Grade D-$5.15-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SHPH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SHPH currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.24) and Max Pain ($5.41) forces dealer call-delta covering toward $46.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SHPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SHPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SHPH Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.3%	-$11.7M	-$9.5M	-45%
FY 2024	$4.00B	52%	-0.2%	-$9.1M	-$7.3M	-45%
FY 2023	$4.00B	52%	-0.1%	-$6.6M	-$5.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SHPH)

✓Walkthrough of SHPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SHPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.73%▲ ASCENDING CHANNEL

2026-11-03O $5.23H $5.23L $5.15C $5.15VOL 20.5K

RES: $6.19SUP: $3.38SMA50: $4.24SMA200: $6.95

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SHPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SHPH Butterfly Map → + Track SHPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SHPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SHPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SHPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SHPH)

Health Care Rank #450 of 1016 ⚔️ CRVO vs SHPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SHPH vs. CRVO, CELU, MIRA, BYSI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Shuttle Pharmaceuticals Holdings Inc. (SHPH) ranks #450 by composite RQD confidence (41/100, grade D-) and #818 by equity capitalization ($24.5M). Within this direct 5-issuer industry benchmark cohort, SHPH leads on earnings valuation at N/A trailing P/E, while SHPH leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SHPH currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SHPH ACTIVE Shuttle Pharmaceuticals Holdings Inc.	D-	41/100	—	—	-35.0%	-1.53%	$24.5M	Benchmark Subject
CRVO CervoMed Inc.	E	28/100	—	—	-35.0%	-8.57%	$24.2M	/crvo-vs-shph →
CELU Celularity Inc. (Class A)	E	26/100	—	24.4%	-35.0%	-5.79%	$26.0M	/celu-vs-shph →
MIRA MIRA Pharmaceuticals Inc.	D-	36/100	—	—	-35.0%	-4.04%	$23.0M	/mira-vs-shph →
BYSI BeyondSpring Inc.	D-	37/100	—	—	-35.0%	+24.60%	$26.5M	/bysi-vs-shph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001757499

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shuttle Pharmaceuticals Holdings Inc. (SHPH) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.7M, operating cash flow of -$9.5M, and free cash flow of -$9.5M (-29.4% YoY). On the balance sheet, SHPH closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.7M	-$9.5M	-$9.5M	$10.5M	—
FY2024 (FY)	2024-12-31	$0	-$9.1M	-$7.3M	-$7.3M	$2.5M	—
FY2023 (FY)	2023-12-31	$0	-$6.6M	-$5.6M	-$5.6M	—	—

3. SHPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SHPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SHPH compare to CRVO and CELU in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SHPH?

Where is SHPH trading relative to its 50-day, 200-day, and 52-week technical levels?

SHPH last traded at $5.15 (-1.53% on volume of 20,484 shares), positioning the stock +21.46% above its 50-day simple moving average ($4.24) and -25.90% below its 200-day simple moving average ($6.95). Across its 52-week range of $2.58 to $44.40, SHPH sits at the 6.1% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.51 to $5.79).

SHPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Shuttle Pharmaceuticals Holdings Inc. (SHPH)?

In FY 2025 (10-K), SHPH converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SHPH RQD Cockpit SHPH 12M Forecast SHPH Earnings & Move SHPH Dividends & DRIP SHPH Insiders & 13F SHPH Whale Options SHPH Profit Sankey SHPH News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SHPH — Shuttle Pharmaceuticals Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:21Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SHPH scores 41 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."

Fundamental Cash Engine (7 / 20): Per the RQD rating, ROIC is -35% and FCF yield is 0%. Per the SEC financials, FY 2025 free cash flow was $-9.5M against revenue of $0.0M, so the business is consuming cash rather than generating it. For a prospective investor, there is no cash-flow valuation floor in the source data.
Whale / 13F Flow (9 / 20): The RQD rating assigns 9 / 20 to institutional accumulation and options positioning. The holders section contains no 13F data, so the basis for this score cannot be verified from the source data provided.
Insider Conviction (5 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scores 5 / 20. The holders section is empty, so the individual trades behind this score are not available in source data.
Macro Regime Fit (10 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity scoring 10 / 20. A beta of 1.0 means the stock is expected to move in line with the broad market, offering no defensive cushion.
Forensic Balance Sheet (10 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The weak Piotroski reading indicates poor financial-health signals, while the Altman figure sits in a range that does not by itself signal distress.

Investor implications: The main upside driver cited in the source data is the liquidity signal in the Butterfly graph (see below), which is a macro-positioning factor rather than an operating one. The valuation tradeoff is stark: with negative ROIC, zero FCF yield, and a market capitalization of $24.9M, the equity rests on future outcomes that the provided financials do not evidence. The 52-week range of $2.58 - $44.4 shows extreme price dispersion, which signals high volatility for a prospective holder.

Business

Shuttle Pharmaceuticals Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M for each of FY 2025, FY 2024, and FY 2023. Not available in source data: product pipeline, end customers, and monetization mechanism.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-11.9M	$-11.7M	N/A	$-9.5M	$0.3M	N/A
FY 2024	$0.0M	$-7.7M	$-9.1M	N/A	$-7.3M	$1.9M	N/A
FY 2023	$0.0M	$-5.9M	$-6.6M	N/A	$-5.6M	N/A	N/A

Per the SEC financials, the company reported operating losses in every period shown, with operating loss widening from $-5.9M (FY 2023) to $-11.9M (FY 2025). Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Cash declined from $1.9M to $0.3M between FY 2024 and FY 2025, and debt is not available in source data.

Recent Catalysts & News Wire Analysis

Auditor transition (highest-weight item): A Stock Titan headline reports an auditor exit awaiting Q3 reporting with no successor engaged as of Oct. 16. This is a governance risk watch item.
Market wire items: TradingView, ChartMill, Yahoo! Finance Canada, Up Down Ratio, and TradingKey items reference SHPH price action and positioning. Their summaries are generic templates and do not contain specific fundamental catalysts. One item reports the stock slipping 1.83% to $5.35.
Proprietary liquidity signal: Per the Butterfly graph, a LIQUIDITY_TAILWIND signal is BULLISH with severity 89 and a Macro Tailwind Score of 90/100. The signal cites a 2.77x Net Liquidity beta with r = -0.16, and a True Net Liquidity Index of $5,745.73B (-0.64% 4-week RoC; High-Yield OAS +2 bps). The correlation is weak (r = -0.16), so the signal should be weighed with caution.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly graph, supply_chain is NONE and butterfly_links is empty, so no upstream or downstream dependencies are mapped. Not available in source data: supplier, customer, and partner relationships. The only sector context is Health Care / Biotechnology: Pharmaceutical Preparations. Investors should watch the auditor transition as a 2nd-order governance bottleneck, since an unfilled audit role could delay reporting. The liquidity beta is a macro sensitivity rather than an operating linkage, and its weak correlation limits its predictive use.

Open Questions

Who is the current auditor, and has a successor been engaged ahead of Q3 reporting?
What is the company's product pipeline, and what drives any future revenue given zero reported revenue in FY 2023–FY 2025?
What is the total debt balance, since debt is listed as N/A in every reported period?
What is the basis for the 13F and insider scores in the RQD rating, given that the holders section is empty?
How does the company fund operating losses, given cash fell to $0.3M by FY 2025 against FCF of $-9.5M?

SHPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Shuttle Pharmaceuticals Holdings Inc. (SHPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SHPH Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 18h ago

Shuttle Pharmaceuticals Holdings, Inc. Estimates – NASDAQ:SHPH

TradingView report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 21h ago

Let's take a look at the stocks that are in motion in today's session.

ChartMill report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An auditor exit awaits Q3 reporting at Shuttle Pharma (SHPH), with no successor engaged as of Oct. 16.

Stock Titan report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Citius Oncology, Inc. (CTOR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Shuttle Pharmaceuticals (SHPH) Slips 1.83% to $5.35, Nearing Key Support - Up Down Ratio

https://www.dars.gov.et/ report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Largest Companies by Market Cap: U.S. Stocks

TradingKey report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

Traders are paying attention to the gapping stocks in Thursday's session.

ChartMill report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Top Republic Power Group Limited Class A Ordinary Shares (RPGL) Competitors 2026

MarketBeat report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SHPH Bull vs. Bear Conversation Board — What's Your Call at $5.15?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SHPH 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.60 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SHPH (D- • RQD 41/100) a Buy at $5.23?

Welcome to the SHPH (Shuttle Pharmaceuticals Holdings Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.39 (-16.1%)

Spot @ $5.23

Pump the brakes on SHPH — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SHPH, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Shuttle Pharmaceuticals Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.49 (+24.1%)

Spot @ $5.23

SHPH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SHPH, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $5.23 (52-wk range $2.58 - $44.40), any beat on forward guidance forces shorts and underweight funds to chase.